InvestSMART

Vitrafy Life Sciences Limited (ASX:VFY)

ALERT: Price-sensitive ASX Announcement for VFY
Current share price for VFY : $3.110 0.3 (10.68%)+
Announcement
Release
23 Jul 2026 8:29AM
Price at Release
$2.810
Full Release
download
Summary
Vitrafy Life Sciences Limited has entered into a strategic partnership with Hoxworth Blood Center to tackle the impending crisis in red blood cell preservation due to the phasing out of critical legacy cryopreservation technology. This partnership will see Vitrafy deploying its next-generation cryopreservation ecosystem at Hoxworth, marking a significant expansion of its footprint in the US blood network. The collaboration aims to engage with market participants and stakeholders to develop a unified industry response, although it is not expected to generate revenue immediately. This aligns with Vitrafy's strategy to address the industry's needs and create a pathway for substantial commercial scale.
Key Points
  • Vitrafy Life Sciences Limited announces a partnership with Hoxworth Blood Center.
  • The partnership addresses the end-of-life of legacy red blood cell cryopreservation technology.
  • Vitrafy aims to expand its cryopreservation ecosystem solution across the US blood network.
  • Hoxworth Blood Center is one of the oldest and most respected blood centers in the United States.
  • The partnership involves placing a cryopreservation freezing and software package at Hoxworth.
  • Vitrafy does not expect immediate revenue generation from this partnership.
  • The collaboration aims for a broader engagement with market participants and government stakeholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.